NEW ZEALAND DATA SHEET

1. SEVORANE VOLATILE LIQUID FOR INHALATION 100%

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SEVORANE is comprised only of the active ingredient sevoflurane 100%.

3. PHARMACEUTICAL FORM

Volatile liquid for inhalation.

Sevoflurane is a non-flammable and non-explosive liquid administered by vaporisation. It is a clear, colourless, non-pungent liquid. At least 300ppm of water is present to provide protection from environmental Lewis acids. No other additives or chemical stabilisers are utilised. It is miscible with ethanol, ether, chloroform and petroleum benzene and is slightly soluble in water.

Sevoflurane has the following physical and chemical properties:

<table>
<thead>
<tr>
<th>Physical/Chemical Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boiling Point at 760 mm Hg</td>
<td>58.6°C</td>
</tr>
<tr>
<td>Specific Gravity at 20°C</td>
<td>1.520 - 1.525</td>
</tr>
<tr>
<td>Vapor pressure in mm Hg</td>
<td>157 mm Hg at 20°C</td>
</tr>
<tr>
<td></td>
<td>197 mm Hg at 25°C</td>
</tr>
<tr>
<td></td>
<td>317 mm Hg at 36°C</td>
</tr>
</tbody>
</table>

The equation for calculated vapour pressure in mm Hg: \( \log_{10} P_{vap} = A + \frac{B}{T} \)

Where: \( A = 8.086 \); \( B = -1726.68 \); \( T = ^\circ C + 273.16^\circ K \) (Kelvin)

Distribution Partition Coefficients at 37°C:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood / Gas</td>
<td>0.63 - 0.69</td>
</tr>
<tr>
<td>Water / Gas</td>
<td>0.36</td>
</tr>
<tr>
<td>Olive Oil / Gas</td>
<td>47.2 - 53.9</td>
</tr>
<tr>
<td>Brain / Gas</td>
<td>1.15</td>
</tr>
</tbody>
</table>

Mean Component/Gas Partition Coefficients at 25°C for polymers commonly used in medical applications:

<table>
<thead>
<tr>
<th>Polymer</th>
<th>Mean Component/Gas Partition Coefficients at 25°C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conductive rubber</td>
<td>14.0</td>
</tr>
<tr>
<td>Butyl rubber</td>
<td>7.7</td>
</tr>
<tr>
<td>Polyvinyl chloride</td>
<td>17.4</td>
</tr>
<tr>
<td>Polyethylene</td>
<td>1.3</td>
</tr>
</tbody>
</table>

Sevoflurane is nonflammable and non-explosive as defined by the requirements of International Electrotechnical Commission 601-2-13.
4. CLINICAL PARTICULARS

4.1 Therapeutic indications
Sevoflurane may be used for induction and maintenance of general anaesthesia in adult and paediatric patients for inpatient and outpatient surgery.

4.2 Dose and method of administration
The concentration of sevoflurane being delivered from a vaporiser during anaesthesia should be known. This may be accomplished by using a vaporiser calibrated specifically for sevoflurane.

Premedication
Premedication should be selected according to the needs of the individual patient, and at the discretion of the anaesthetist.

Induction
Dosage should be individualised and titrated to the desired effect according to the patient's age and clinical status. A short acting barbiturate or other intravenous induction agent may be administered followed by inhalation of sevoflurane. Induction with sevoflurane may be achieved in oxygen or in combination with oxygen-nitrous oxide mixtures. For induction of anaesthesia, inspired concentrations of up to 8% sevoflurane usually produces surgical anaesthesia in less than two minutes in both adults and children.

Maintenance
Surgical levels of anaesthesia may be sustained with concentrations of 0.5 - 3% sevoflurane with or without the concomitant use of nitrous oxide (see table).

<p>| Minimum Alveolar Concentration (MAC) Values for Adults and Paediatric Patients According to Age |</p>
<table>
<thead>
<tr>
<th>Age of Patient (Years)</th>
<th>Sevoflurane in Oxygen</th>
<th>Sevoflurane in 65% N₂O/35% O₂</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 1 months</td>
<td>3.3%</td>
<td></td>
</tr>
<tr>
<td>1 - &lt;6 months</td>
<td>3.0%</td>
<td></td>
</tr>
<tr>
<td>6 months - &lt;3 years</td>
<td>2.8%</td>
<td>2.0%</td>
</tr>
<tr>
<td>3 – 12</td>
<td>2.5%</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>2.6%</td>
<td>1.4%</td>
</tr>
<tr>
<td>40</td>
<td>2.1%</td>
<td>1.1%</td>
</tr>
<tr>
<td>60</td>
<td>1.7%</td>
<td>0.9%</td>
</tr>
<tr>
<td>80</td>
<td>1.4%</td>
<td>0.7%</td>
</tr>
</tbody>
</table>

* Neonates are full-term gestational age. MAC in premature infants has not been determined.
** In 3 - <5; 1 - <3 year old paediatric patients, 60% N₂O/40% O₂ was used.

Emergence
Emergence times are generally short following sevoflurane anaesthesia. Therefore, patients may require post-operative pain relief earlier.
Use in Special Populations

**Hepatic impairment**
Sevoflurane is effective and well-tolerated when used as the primary agent for the maintenance of anaesthesia in patients with impaired hepatic function, Child-Pugh Class A and B. Sevoflurane did not exacerbate pre-existing hepatic impairment.

**Renal impairment**
See section 4.4 Special warnings and precautions for use.

**Elderly**
As with other inhalation agents, lesser concentrations of sevoflurane are normally required to maintain anaesthesia.

**Paediatric population**
Sevoflurane may be used for induction and maintenance of general anaesthesia in paediatric patients for inpatient and outpatient surgery. See also section 4.4 Special warnings and precautions for use.

4.3 **Contraindications**
Sevoflurane should not be used in patients with known sensitivity to sevoflurane or to other halogenated agents (e.g. history of hepatotoxicity, usually including elevated liver enzymes, fever, leukocytosis and/or eosinophilia temporally related to anaesthesia with one of these agents) or with known or suspected genetic susceptibility to malignant hyperthermia.

4.4 **Special warnings and precautions for use**
Sevoflurane may cause respiratory depression, which may be augmented by narcotic premedication or other agents causing respiratory depression. Respiration should be supervised and if necessary, assisted.

Sevoflurane should be administered only by persons trained in the administration of general anaesthesia. Facilities for maintenance of a patent airway, artificial ventilation and oxygen enrichment and circulatory resuscitation must be immediately available. The concentration of sevoflurane being delivered from a vaporiser must be known exactly. As volatile anaesthetics differ in their physical properties, only vaporisers specifically calibrated for sevoflurane must be used. The administration of general anaesthesia must be individualised based on the patient’s response. Hypotension and respiratory depression increase as anaesthesia is deepened.

Isolated reports of QT prolongation, very rarely associated with torsade de pointes (in exceptional cases, fatal), have been received. Caution should be exercised when administering sevoflurane to susceptible patients.

Isolated cases of ventricular arrhythmia were reported in paediatric patients with Pompe’s disease.

Caution should be exercised in administering general anaesthesia, including sevoflurane, to patients with mitochondrial disorders.

During maintenance of anaesthesia, increasing the concentration of sevoflurane produces dose-dependent decreases in blood pressure. Excessive decrease in blood pressure may be related to depth of anaesthesia and in such instances may be corrected by decreasing the inspired concentration of sevoflurane.
As with all anaesthetics, maintenance of haemodynamic stability is important to the avoidance of myocardial ischaemia in patients with coronary artery disease.

The recovery from general anaesthesia should be assessed carefully before patients are discharged from the post-anaesthesia care unit.

**Replacement of Desiccated CO₂ Absorbents**

Rare cases of extreme heat, smoke, and/or spontaneous fire in the anaesthesia machine have been reported during sevoflurane use in conjunction with the use of desiccated CO₂ absorbent, specifically those containing potassium hydroxide (e.g. Baralyme®). An unusually delayed rise or unexpected decline of inspired sevoflurane concentration compared to the vaporiser setting may be associated with excessive heating of the CO₂ absorbent canister.

An exothermic reaction, enhanced sevoflurane degradation, and production of degradation products (see section 6.2 Incompatibilities) can occur when the CO₂ absorbent becomes desiccated, such as after an extended period of dry gas flow through the CO₂ absorbent canisters. Sevoflurane degradants (methanol, formaldehyde, carbon monoxide, and Compounds A, B, C and D) were observed in the respiratory circuit of an experimental anaesthesia machine using desiccated CO₂ absorbents and maximum sevoflurane concentrations (8%) for extended periods of time (≥2 hours).

Concentrations of formaldehyde observed at the anaesthesia respiratory circuit (using sodium hydroxide containing absorbents) were consistent with levels known to cause mild respiratory irritation. The clinical relevance of the degradants observed under this extreme experimental model is unknown.

When a clinician suspects that the CO₂ absorbent may be desiccated, it should be replaced before administration of sevoflurane. The colour indicator of most CO₂ absorbents does not necessarily change as a result of desiccation. Therefore, the lack of significant colour change should not be taken as an assurance of adequate hydration. CO₂ absorbents should be replaced routinely regardless of the state of the colour indicator.

**Malignant Hyperthermia**

In susceptible individuals, potent inhalation anaesthetic agents, including sevoflurane, may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia. The clinical syndrome is signaled by hypercapnia, and may include muscle rigidity, tachycardia, tachypnoea, cyanosis, arrhythmias, and/or unstable blood pressure. Some of these non-specific signs may also appear during light anaesthesia, acute hypoxia, hypercapnia and hypovolemia.

In clinical trials, one case of malignant hyperthermia was reported. In addition, there have been post-marketing reports of malignant hyperthermia. Some of these reports have been fatal.

Treatment of malignant hyperthermia includes discontinuation of triggering agents (e.g. sevoflurane), administration of intravenous dantrolene sodium (consult prescribing information for intravenous dantrolene sodium for additional information on patient management), and application of supportive therapy. Such therapy includes vigorous efforts to restore body temperature to normal, respiratory and circulatory support as indicated, and management of electrolyte-fluid-acid-base abnormalities. Renal failure may appear later, and urine flow should be monitored and sustained if possible.
Hyperkalaemic Cardiac Arrest in Paediatric Patients
Use of inhaled anaesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in paediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatine kinase levels and, in some cases, changes in urine consistent with myoglobinuria. Despite the similarity in presentation to malignant hyperthermia, none of these patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state. Early and aggressive intervention to treat the hyperkalaemia and resistant arrhythmias is recommended, as is subsequent evaluation for latent neuromuscular disease.

Paediatric Use
The use of sevoflurane has been associated with seizures. Many of these have occurred in children and young adults starting from 2 months of age, most of whom had no predisposing risk factors. Clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures (see section 4.8 Undesirable effects).

Elderly
MAC decreases with increasing age. The average concentration of sevoflurane to achieve MAC in an 80 year old is approximately 50% of that required in a 20 year old.

Renal Impairment
Because of the small number of patients with renal insufficiency (baseline serum creatinine greater than 1.5 mg/dL) studied, the safety of sevoflurane administration in this group has not been fully established. Therefore, sevoflurane should be used with caution in patients with renal insufficiency.

Hepatic Impairment
Very rare cases of mild, moderate and severe post-operative hepatic dysfunction or hepatitis with or without jaundice have been reported from postmarketing experiences.

Clinical judgment should be exercised when sevoflurane is used in patients with underlying hepatic conditions or under treatment with medicines known to cause hepatic dysfunction (see section 4.8 Undesirable effects).

It has been reported that previous exposure to halogenated hydrocarbon anaesthetics, especially if the interval is less than 3 months, may increase the potential for hepatic injury.

Neurosurgery
In patients at risk for elevations of intracranial pressure (ICP), sevoflurane should be administered cautiously in conjunction with ICP-reducing manoeuvres such as hyperventilation.

Seizures
Rare cases of seizures have been reported in association with sevoflurane use (see Section 4.4 Special warnings and precautions for use – Paediatric Use, and Section 4.8 Undesirable Effects).
4.5 Interaction with other medicines and other forms of interaction

Beta-sympathomimetic agents like isoprenaline and alpha- and beta-sympathomimetic agents like adrenaline and noradrenaline should be used with caution during sevoflurane narcosis, due to a potential risk of ventricular arrhythmia.

Non-selective MAO-inhibitors: Risk of crisis during the operation. It is generally recommended that treatment should be stopped 2 weeks prior to surgery.

Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists, in particular dihydropyridine derivatives.

Caution should be exercised when calcium antagonists are used concomitantly with inhalation anesthetics due to the risk of additive negative inotropic effect.

Concomitant use of succinylcholine with inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in paediatric patients during the post-operative period.

Sevoflurane has been shown to be safe and effective when administered concurrently with a wide variety of agents commonly encountered in surgical situations such as central nervous system agents, autonomic medicines, skeletal muscle relaxants, anti-infective agents including aminoglycosides, hormones and synthetic substitutes, blood derivatives and cardiovascular medicines including epinephrine. Sevoflurane administration is compatible with barbiturates as commonly used in surgical practice.

Benzodiazepines and Opioids

Benzodiazepines and opioids are expected to decrease the MAC of sevoflurane in the same manner as with other inhalational anesthetics. Sevoflurane administration is compatible with benzodiazepines and opioids as commonly used in surgical practice.

Inducers of CYP2E1

Medicinal products and compounds that increase the activity of cytochrome P450 isoenzyme CYP2E1, such as isoniazid and alcohol, may increase the metabolism of sevoflurane and lead to significant increases in plasma fluoride concentrations (see Section 5.2 Pharmacokinetic properties – Fluoride Ion).

Nitrous Oxide

As with other halogenated volatile anesthetics, the MAC of sevoflurane is decreased when administered in combination with nitrous oxide. The MAC equivalent is reduced approximately 50% in adult and approximately 25% in paediatric patients.

Neuromuscular Blocking Agents

As with other inhalational anaesthetic agents, sevoflurane affects both the intensity and duration of neuromuscular blockade by non-depolarizing muscle relaxants. When used to supplement alfentanil-N₂O anaesthesia, sevoflurane potentiates neuromuscular block induced with pancuronium, vecuronium or atracurium. The dosage adjustments for these muscle relaxants when administered with sevoflurane are similar to those required with isoflurane. The effect of sevoflurane on suxamethonium chloride and the duration of depolarizing neuromuscular blockade has not been studied.

Dosage reduction of neuromuscular blocking agents during induction of anaesthesia may result in delayed onset of conditions suitable for endotracheal intubation or inadequate muscle relaxation because potentiation of neuromuscular blocking agents is observed a few minutes after the beginning of sevoflurane administration.
Among non-depolarizing agents, vecuronium, pancuronium and atracurium interactions have been studied. In the absence of specific guidelines: (1) for endotracheal intubation, do not reduce the dose of non-depolarizing muscle relaxants, (2) during maintenance of anaesthesia, the dose of non-depolarizing muscle relaxants is likely to be reduced compared to that during N₂O/opioid anaesthesia. Administration of supplemental doses of muscle relaxants should be guided by the response to nerve stimulation.

4.6 Fertility, pregnancy and lactation

Fertility
Reproduction studies in rats and rabbits at doses up to 1 MAC have revealed no evidence of impaired fertility or harm to the foetus due to sevoflurane.

Pregnancy
Pregnancy Category B2. Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human foetus having been observed.

Studies in animals are inadequate or may be lacking, but available data show no evidence of an increased occurrence of foetal damage.

Published animal studies of some anaesthetic/sedation drugs have reported adverse effects on brain development in early life (see section 5.3 Preclinical safety data).

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, sevoflurane should be used during pregnancy only if clearly needed.

The safety of sevoflurane has been demonstrated in a clinical trial of anaesthesia for Caesarean section. The safety of sevoflurane in labor and vaginal delivery has not been demonstrated.

Sevoflurane, like other inhalational agents, has relaxant effects on the uterus with the potential risk for uterine bleeding. Clinical judgment should be observed when using sevoflurane during obstetric anaesthesia.

Breastfeeding
It is not known whether sevoflurane or its metabolites is excreted in human milk. Due to the absence of documented experience, women should be advised to skip breastfeeding for 48 hours after administration of sevoflurane and discard milk produced during this period.

4.7 Effects on ability to drive and use machines

As with other agents, patients should be advised that performance of activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, may be impaired for some time after general anaesthesia (see section 4.4 Special warnings and precautions for use).

Patients should not be allowed to drive for a suitable period after sevoflurane anaesthesia.
4.8 Undesirable effects

Clinical Trials
As with all potent inhaled anaesthetics, sevoflurane may cause dose-dependent cardio-respiratory depression. Most adverse events are mild or moderate in severity and transient in duration.

Nausea, vomiting, and delirium have been observed in the postoperative period, common sequelae of surgery and general anaesthesia, which may be due to inhalational anaesthetic, other agents administered intra-operatively or post-operatively and to the patient's response to the surgical procedure.

The most frequent adverse events (≥10%) considered to be probably related to sevoflurane administration overall were: nausea, vomiting, increased cough, and hypotension.

In adult patients the most frequent adverse events (≥10%) were: nausea, vomiting, and hypotension.

In elderly patients the most frequent adverse events (≥10%) were: hypotension, nausea, and bradycardia.

In paediatric patients, the most frequent adverse events (≥10%) were: vomiting, agitation, increased cough, and nausea.

The type, severity and frequency of adverse events in sevoflurane patients were comparable to adverse events in reference medicine patients.

All events, at least possibly related to sevoflurane from clinical trials, are displayed in the Table below by MedDRA System Organ Class, Preferred Term and frequency. The following frequency groupings are used: very common (≥1/10); common (≥1/100 and <1/10); uncommon (≥1/1,000 and <1/100); rare (≥1/10,000 and <1/1,000); very rare (<1/10,000), including isolated reports. The type, severity, and frequency of adverse events in sevoflurane patients were comparable to adverse events in reference medicine patients.
### Summary of Most Frequent Adverse Drug Reactions in Sevoflurane Clinical Trials

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Frequency</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychiatric disorders</td>
<td>Very Common</td>
<td>Agitation</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Common</td>
<td>Somnolence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dizziness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Headache</td>
</tr>
<tr>
<td>Cardiac/vascular disorders</td>
<td>Very Common</td>
<td>Bradycardia</td>
</tr>
<tr>
<td></td>
<td>Common</td>
<td>Hypotension</td>
</tr>
<tr>
<td></td>
<td>Uncommon</td>
<td>Tachycardia</td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td>Hypertension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atrioventricular block complete</td>
</tr>
<tr>
<td></td>
<td></td>
<td>QT prolongation associated with Torsade</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal</td>
<td>Very Common</td>
<td>Cough</td>
</tr>
<tr>
<td>disorders</td>
<td>Common</td>
<td>Respiratory disorder</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Laryngismus</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Very Common</td>
<td>Nausea</td>
</tr>
<tr>
<td></td>
<td>Common</td>
<td>Vomiting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased salivation</td>
</tr>
<tr>
<td>General disorders and administration</td>
<td>Common</td>
<td>Chills</td>
</tr>
<tr>
<td>site conditions</td>
<td></td>
<td>Pyrexia</td>
</tr>
<tr>
<td>Investigations</td>
<td>Common</td>
<td>Blood glucose elevation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Liver function test abnormal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>White blood cell count elevation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fluoride increased</td>
</tr>
<tr>
<td>Injury, poisoning and procedural</td>
<td>Common</td>
<td>Hypothermia</td>
</tr>
<tr>
<td>complications</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In clinical studies administration of sevoflurane has not been associated with any clinically significant effect on liver or kidney function in a wide variety of patient populations including: children, adults, elderly, renally impaired, hepatically impaired, obese, patients undergoing cardiac bypass surgery, patients treated with aminoglycerides or metabolic inducers, patients exposed to repeat surgeries, patients undergoing surgeries 6 hours in duration.

**Post Marketing Experience**
Adverse events have been spontaneously reported during post-approval use of sevoflurane. These events are reported voluntarily from a population of an unknown rate of exposure. Therefore, it is not possible to estimate the true incidence of adverse events or establish a causal relationship to sevoflurane exposure.
### Summary of Post-Marketing Adverse Drug Events

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune system disorders</td>
<td>Anaphylactic reaction***&lt;br&gt;Hypersensitivity***&lt;br&gt;Anaphylactoid reaction</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Convulsion&lt;br&gt;Dystonia</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Cardiac arrest#</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Bronchospasm&lt;br&gt;Dyspnoea***&lt;br&gt;Wheezing***</td>
</tr>
<tr>
<td>Hepato-biliary disorders</td>
<td>Hepatitis&lt;br&gt;Hepatic failure&lt;br&gt;Hepatic necrosis</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Rash***&lt;br&gt;Urticaria&lt;br&gt;Pruritus&lt;br&gt;Dermatitis contact***&lt;br&gt;Swelling Face***</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Hyperthermia malignant&lt;br&gt;Chest discomfort***</td>
</tr>
</tbody>
</table>

*** May be associated with hypersensitivity reactions, particularly in association with long-term occupational exposure to inhaled anaesthetic agents.
# There have been very rare postmarketing reports of cardiac arrest in the setting of sevoflurane use.

Seizure-like activity may occur on extremely rare occasions following sevoflurane administration. Reported events were of short duration and there was no evidence of any abnormality during emergence from anaesthesia or in the postoperative period.

### Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions to [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/).

### 4.9 Overdose

In the event of overdosage the following action should be taken: discontinue administration of sevoflurane, maintain a patent airway, initiate assisted or controlled ventilation with oxygen and maintain adequate cardiovascular function.

For advice on the management of overdose, please contact the National Poisons Centre on 0800 POISON (0800 764766).
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Anaesthetics, general – ATC code: N01A

Sevoflurane has been demonstrated to be a fast-acting, non-irritating anaesthetic agent in a variety of animal species and in humans. Administration has been associated with a smooth, rapid loss of consciousness during inhalation induction and a rapid recovery following discontinuation of anaesthesia.

Induction is accomplished, with a minimum of excitement or of signs of upper respiratory irritation, no evidence of excessive secretions within the tracheobronchial tree and no central nervous system stimulation. In paediatric studies in which mask induction was performed, the incidence of coughing was statistically significantly lower with sevoflurane than with halothane. The times for induction and recovery were also reduced in these patients.

Like other potent inhalational anaesthetics, sevoflurane depresses respiratory function and blood pressure in a dose-related manner. Sevoflurane has been demonstrated to be an appropriate agent for use in neurosurgery, Caesarean section, coronary artery bypass surgery and in non-cardiac patients at risk for myocardial ischaemia.

The adrenaline-induced arrhythmogenic threshold for sevoflurane is comparable to that of isoflurane and higher than that of halothane. Studies in dogs have demonstrated that sevoflurane does not reduce collateral myocardial perfusion. In clinical studies, the incidence of myocardial ischaemia and myocardial infarction in patients at risk for myocardial ischaemia was comparable between sevoflurane and isoflurane.

Animal studies have shown that regional blood flow (e.g., hepatic, renal, cerebral circulations) is well maintained with sevoflurane. In both animal studies (dogs, rabbits) and clinical studies, changes in neurohaemodynamics (intracranial pressure, cerebral blood flow/blood flow velocity, cerebral metabolic rate for oxygen, and cerebral perfusion pressure) were comparable between sevoflurane and isoflurane. Sevoflurane has minimal effect on intra-cranial pressure and preserves CO₂ responsiveness.

Sevoflurane does not affect renal concentrating ability, even after prolonged anaesthetic exposure of up to approximately 9 hours.

For minimum alveolar concentration (MAC) equivalents for sevoflurane for various age groups, see Section 4.2 Dosage and administration. As with other halogenated agents, MAC decreases with age and with the addition of nitrous oxide.

Paediatric population
The use of sevoflurane has been associated with seizures. Many of these have occurred in children and young adults starting from 2 months of age, most of whom had no predisposing risk factors. Clinical judgment should be exercised when using sevoflurane in patients who may be at risk for seizures.
Description of Clinical Studies, Safety

**Paediatric**
Some published studies in children have observed cognitive deficits after repeated or prolonged exposures to anaesthetic agents early in life. These studies have substantial limitations, and it is not clear if the observed effects are due to the anaesthetic/sedation drug administration or other factors such as the surgery or underlying illness. In addition, more recent published registry studies did not confirm these findings.

Published animal studies of some anaesthetic/sedation drugs have reported adverse effects on brain development in early life (see Section 5.3 Preclinical safety data).

5.2 Pharmacokinetic properties

**Absorption**
The low solubility of sevoflurane in blood would suggest that alveolar concentrations should rapidly increase upon induction and rapidly decrease upon cessation of the inhaled agent. This was confirmed in a clinical study where inspired and end-tidal concentrations (F\textsubscript{I} and F\textsubscript{A}) were measured. The F\textsubscript{A}/F\textsubscript{I} (washin) value at 30 minutes for sevoflurane was 0.85. The F\textsubscript{A}/F\textsubscript{AO} (washout) value at 5 minutes was 0.15.

**Distribution**
The effects of sevoflurane on the displacement of medicines from serum and tissue proteins have not been investigated. Other fluorinated volatile anaesthetics have been shown to displace medicines from serum and tissue proteins in vitro. The clinical significance of this is unknown. Clinical studies have shown no untoward effects when sevoflurane is administered to patients taking medicines that are highly bound and have a small volume of distribution (e.g. phenytoin).

**Metabolism**
The rapid pulmonary elimination of sevoflurane minimises the amount of anaesthetic available for metabolism. In humans <5% of sevoflurane absorbed is metabolised to hexafluoroisopropanol (HFIP), with release of inorganic fluoride and carbon dioxide (or a one carbon fragment). Once formed HFIP is rapidly conjugated with glucuronic acid and eliminated. No other metabolic pathways for sevoflurane have been identified. It is the only fluorinated volatile anaesthetic that is not metabolised to trifluoroacetic acid.

**Fluoride Ion**
Fluoride ion concentrations are influenced by the duration of anaesthesia, the concentration of sevoflurane administered, and the composition of the anaesthetic gas mixture.

Inorganic fluoride concentrations peak within two hours of the end of sevoflurane anaesthesia and return to baseline concentrations within 48 hours post-anaesthesia. Approximately 7% of adults evaluated for inorganic fluoride concentrations in Abbott clinical studies experienced concentrations greater than 50 M; no clinically significant effect on renal function was observed in any of these individuals (see section 4.5 Interactions with other medicines – Inducers of CYP2E1).

The defluorination of sevoflurane is not inducible by barbiturates.
5.3 Preclinical safety data

Published studies in pregnant and juvenile animals suggest that the use of anaesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity during the period of rapid brain growth or synaptogenesis may result in neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis when used for longer than 3 hours.

These studies included anaesthetic agents from a variety of drug classes. The clinical significance of these nonclinical findings is yet to be determined (see Section 5.1 Pharmacodynamic properties - Description of Clinical Studies, Safety).

Carcinogenicity /Mutagenicity

Studies on carcinogenesis have not been performed. No mutagenic effect was noted in the Ames test and no chromosomal aberrations were induced in cultured mammalian cells.

Compound A

The LC_{50} of compound A in Wistar rats was 1050-1090ppm in animals exposed for 1 hour and 400-420ppm in animals exposed for 3 hours (median lethal concentrations were approximately 1070 and 330-490ppm, respectively). In rats exposed to 30, 60, or 120ppm of Compound A in an 8-week chronic toxicity study (24 exposures, 3 hours/exposure), no apparent evidence of toxicity was observed other than loss of body weight in females on the last study day.

Sprague-Dawley rats were administered Compound A via nose-only inhalation exposure in an open system (25, 50, 100 or 200ppm [0.0025-0.02%] of Compound A). Control groups were exposed to air. The threshold, at which reversible alterations in urinary and clinical parameters indicative of renal changes (concentration-dependent increases in BUN, creatinine, glucose, protein/creatinine ratios and N-acetyl-glucosamidase/creatinine ratios) were observed, was 114ppm of Compound A. Histological lesions were all reversible.

Since the uptake of inhalational agents in small rodents is substantially higher than in humans, higher levels of medicine, Compound A (degradant of sevoflurane) or 2-bromo-2-chloro-1, 1-difluoro ethylene (BCDFE) (degradant/metabolite of halothane) would be expected in rodents. Also, the activity of the key enzyme (β-lyase) involved in haloalkene nephrotoxicity is ten-fold greater in the rat than it is in humans.

Compound A concentrations are reported to increase with increasing absorber temperature, increasing sevoflurane concentrations and with decreasing fresh gas flow rates. It has been reported that the concentration of Compound A increases significantly with prolonged dehydration of Baralyme®. In the clinical situation, the highest concentration of Compound A in the anaesthesia circuit with soda lime as the CO_{2} absorbent was 15 ppm in children and 32 ppm in adults. However, concentrations to 61 ppm have been observed in patients attached to systems with Baralyme® as the CO_{2} absorbent.

The level of Compound A at which toxicity occurs in humans is not known. Although exposure to sevoflurane in low flow systems is limited, there has been no evidence of renal dysfunction attributable to Compound A.

Compound B

In the clinical situation, the concentration of Compound B detected in the anaesthesia circuit did not exceed 1.5 ppm. Inhalation exposure to Compound B at concentrations of up to 2400 ppm (0.24%) for 3 hours resulted in no adverse effects on renal parameters or tissue histology in Wistar rats.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Water (as a Lewis Acid Inhibitor).

6.2 Incompatibilities
Sevoflurane is stable when stored under normal room lighting conditions. No discernible degradation of sevoflurane occurs in the presence of strong acids or heat. Sevoflurane is not corrosive to stainless steel, brass, aluminium, nickel-plated brass, chrome-plated brass, or copper beryllium alloy.

Chemical degradation can occur upon exposure of inhaled anaesthetics to CO₂ absorbent within the anaesthesia machine. When used as directed with fresh absorbents, degradation of sevoflurane is minimal, and degradants are undetectable or non-toxic. Sevoflurane degradation and subsequent degradant formation are enhanced by increasing absorbent temperature, desiccated CO₂ absorbent (especially potassium hydroxide-containing, e.g. Baralyme®), increased sevoflurane concentration and decreased fresh gas flow. Sevoflurane can undergo alkaline degradation by two pathways. The first results from the loss of hydrogen fluoride with the formation of pentafluoroisopropanyl fluoromethyl ether (PIFE or more commonly known as Compound A). The second pathway for degradation of sevoflurane occurs only in the presence of desiccated CO₂ absorbents and leads to the dissociation of sevoflurane into hexafluoroisopropanol (HFIP) and formaldehyde.

HFIP is inactive, non-genotoxic, rapidly glucuronidated, cleared, and has toxicity comparable to sevoflurane. Formaldehyde is present during normal metabolic processes. Upon exposure to a highly desiccated absorbent, formaldehyde can further degrade into methanol and formate. Formate can contribute to the formation of carbon monoxide, in the presence of high temperature. Methanol can react with Compound A to form the methoxy addition product Compound B. Compound B can undergo further HF elimination to form Compounds C, D and E. With highly desiccated absorbents, especially those containing potassium hydroxide (e.g. Baralyme®), the formation of formaldehyde, methanol, carbon monoxide, Compound A and perhaps some of its degradants, Compounds B, C and D may occur.

6.3 Shelf life
3 years.

6.4 Special precautions for storage
Sevoflurane should be stored at room temperature (below 30°C). Sevoflurane has been demonstrated to be stable for the period defined by the expiration dating on the label.

6.5 Nature and contents of container
Sevoflurane is packaged in 100 mL* or 250 mL amber-coloured glass* and PEN plastic bottles (* not marketed in New Zealand).
6.6 Special precautions for disposal and other handling

Sevoflurane should be administered via a vaporiser calibrated specifically for sevoflurane using a key filling system designed for sevoflurane-specific vaporisers or other appropriate sevoflurane-specific vaporiser filling systems.

Carbon dioxide absorbents should not be allowed to dry out when inhalational anaesthetics are being administered. Some halogenated anaesthetics have been reported to interact with dry carbon dioxide absorbent to form carbon monoxide. However, in order to minimise the risk of formation of carbon monoxide in re-breathing circuits and the possibility of elevated carboxyhaemoglobin levels, CO₂ absorbents should not be allowed to dry out (see section 4.4 Special warnings and precautions for use).

There have been rare cases of excessive heat production, smoke and fire in the anaesthetic machine when sevoflurane has been used in conjunction with a desiccated (dried out) CO₂ absorbent. If the CO₂ absorbent is suspected to be desiccated it should be replaced out (see section 4.4 Special warnings and precautions for use).

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MEDICINE SCHEDULE

Prescription Medicine

8. SPONSOR

AbbVie Limited
6th Floor, 156-158 Victoria Street
Wellington, 6011

Telephone: (0800) 900 030

9. DATE OF FIRST APPROVAL

7 March 1996.

10. DATE OF REVISION OF THE TEXT


Version 9.
### SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All sections</td>
<td>Adoption of the new Medsafe Data Sheet SmPC-style format and content requirements according to NZDS Explanatory Guide, effective 1 March 2017.</td>
</tr>
<tr>
<td>Section 4.6 Fertility, pregnancy and lactation</td>
<td>Additional safety information relating to brain development in early life.</td>
</tr>
<tr>
<td>Section 5.1 Description of Clinical Studies/Safety Paediatric</td>
<td>Additional safety information relating to brain development in early life.</td>
</tr>
<tr>
<td>Section 5.3 Preclinical Safety Data</td>
<td>Additional safety information relating to brain development in early life.</td>
</tr>
</tbody>
</table>